Efficacy of Tie2 receptor antagonism in Angiosarcoma

Neoplasia

Volumn 14, Issue 2, 2012, Pages 131-140

  Hasenstein, Jason R ^a   Kasmerchak, Kelsey ^a   Buehler, Darya ^a   Hafez, Gholam Reza ^a   Cleary, Kevin ^a   Moody, John S ^b   Kozak, Kevin R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Moses Cone Regional Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (6 METHOXY 2 NAPHTHYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)1H IMIDAZOLE; ANGIOPOIETIN RECEPTOR; SUNITINIB; TIE 2 RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY; TUMOR NECROSIS; TUMOR VOLUME; XENOGRAFT;

EID: 84858050678     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111770     Document Type: Article

References (34)

1. Young RJ, Brown NJ, Reed MW, Hughes D, and Woll PJ (2010). Angiosarcoma. Lancet Oncol 11, 983-991.
2. Dim D, Ravi V, Tan J, Hicks D, and Wong M (2007). The actin-bundling motil-ity protein fascin and vascular endothelial growth factor (VEGF) are universally over-expressed in human angiosarcoma. J Clin Oncol 25(18S). Abstract 10068.
3. Itakura E, Yamamoto H, Oda Y, and Tsuneyoshi M (2008). Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 97, 74-81.
4. Zietz C, Rossle M, Haas C, Sendelhofert A, Hirschmann A, Sturzl M, and Lohrs U (1998). MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 153, 1425-1433.
5. Folpe AL, Veikkola T, Valtola R, and Weiss SW (2000). Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 13, 180-185.
6. Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S, and Maki RG (2009). KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 69, 7175-7179.
7. Arbiser JL, Larsson H, Claesson-Welsh L, Bai X, LaMontagne K, Weiss SW, Soker S, Flynn E, and Brown LF (2000). Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol 156, 1469-1476.
8. Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, and Yancopoulos GD (2000). Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 156, 2179-2183.
9. Stacher E, Gruber-Mosenbacher U, Halbwedl I, Dei Tos AP, Cavazza A, Papotti M, Carvalho L, Huber M, Ermert L, and Popper HH (2009). The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets? Lung Cancer 65, 49-55.
10. Rosen A, Thimon S, Ternant D, Machet MC, Paintaud G, and Machet L (2010). Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. Br J Dermatol 163, 225-227.
11. Fuller CK, Charlson JA, Dankle SK, and Russell TJ (2010). Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol 63, e83-e84.
12. Koontz BF, Miles EF, Rubio MA, Madden JF, Fisher SR, Scher RL, and Brizel DM (2008). Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 30, 262-266.
13. Agulnik M, Okuno OS, von Mehren M, Jovanovic B, Brockstein B, Benjamin R, and Evens A (2009). Bevacizumab for the treatment of angiosarcoma: an open label multicenter phase II study. J Clin Oncol 27(15s). Abstract 10522.
14. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, et al. (2009). Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27, 3154-3160.
15. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, et al. (2009). Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27, 3133-3140.
16. von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, and Borden E (2011). Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118, 770-776.
17. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, et al. (2009). Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma group (EORTC study 62043). J Clin Oncol 27, 3126-3132.
18. Huang H, Bhat A, Woodnutt G, and Lappe R (2010). Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10, 575-585.
19. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, et al. (2010). Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 16, 3044-3056.
20. Semones M, Feng Y, Johnson N, Adams JL, Winkler J, and Hansbury M (2007). Pyridinylimidazole inhibitors of Tie2 kinase. Bioorg Med Chem Lett 17, 4756-4760.
21. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, et al. (1997). Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 94, 861-866.
22. [Burkholder TP, Clayton JR, Rempala ME, Henry JR, Knobeloch JM, Mendel D, McLean JA, Hao Y, Barda DA, and Considine EL, et al. Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model. Invest New Drugs, E-pub ahead of print March 1.
23. Dandu R, Zulli AL, Bacon ER, Underiner T, Robinson C, Chang H, Miknyoczki S, Grobelny J, Ruggeri BA, Yang S, et al. (2008). Design and synthesis of dihydro-indazolo(5,4-a)pyrrolo(3,4-c)carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases. Bioorg Med Chem Lett 18, 1916-1921.
24. Gingrich DE, Reddy DR, Iqbal MA, Singh J, Aimone LD, Angeles TS, Albom M, Yang S, Ator MA, Meyer SL, et al. (2003). A new class of potent vascular endo-thelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno(2,1-a)pyrrolo (3,4-c)carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J Med Chem 46, 5375-5388.
25. Ruggeri BA, Robinson C, Angeles T, Wilkinson J 4th, and Clapper ML (2002). The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res 8, 267-274.
26. Arbiser JL, Kau T, Konar M, Narra K, Ramchandran R, Summers SA, Vlahos CJ, Ye K, Perry BN, Matter W, et al. (2007). Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood 109, 560-565.
27. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, et al. (2003). Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278, 35501-35507.
28. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, and McDonald DM (2010). Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70, 2213-2223.
29. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, et al. (2008). Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 10, 527-537.
30. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, Shibuya M, Takakura N, Koh GY, and Mochizuki N (2008). Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 10, 513-526.
31. Fukuhara S, Sako K, Noda K, Nagao K, Miura K, and Mochizuki N (2009). Tie2 is tied at the cell-cell contacts and to extracellular matrix by angiopoietin-1. Exp Mol Med 41, 133-139.
32. Mark RJ, Poen JC, Tran LM, Fu YS, and Juillard GF (1996). Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77, 2400-2406.
33. Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, Rees R, and Sondak VK (2003). Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 98, 1716-1726.
34. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, et al. (2008). Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol 26, 5269-5274.